Compare HSBC Holdings plc (HSBC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Novartis AG — how do they compare? HSBC Holdings plc trades at $103.71 (market cap $356.97B), while Novartis AG trades at $151.8 (market cap $291.04B). The key difference: HSBC Holdings plc is the larger of the two by market cap, and HSBC Holdings plc pays the higher dividend (3.6%). Which is the better fit depends on your goals.
| HSBC | NVS | |
|---|---|---|
Market Cap | $356.97B | $291.04B |
Sector | Technology | Health |
52-Week High | $107.86 | $168.62 |
52-Week Low | $63.84 | $121.20 |
Dividend Yield | 3.6% | 3.11% |
Enterprise Value | — | $332.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.88% with a bullish technical signal supported by moving averages. The bank reported strong Q2 2026 earnings with 7% revenue growth and a $1 billion buyback announcement. Net income margin improved to 34.54% with ROE at 12.44%, though P/E of 14.87 suggests moderate valuation. Recent news highlights leadership changes and China regulatory impacts.
Outlook remains positive with earnings momentum and shareholder returns, but risks include China exposure and competitive pressures. Analyst consensus shows 38% buy ratings with institutional accumulation, though Citi's downgrade to neutral signals caution after the stock's 40% run-up this year.
Novartis (NVS) trades at $151.72, down 1.87% amid bearish technical signals but maintains strong fundamentals with $56.67B revenue and 22.5% net margin. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.41 vs. $2.17 expected, while recent patent defense for Entresto and strong oncology drug performance provide stability. Analyst consensus leans cautious with 68% Hold ratings, though institutional buying activity indicates underlying confidence in the pharmaceutical giant's pipeline.
Investment outlook balances robust profitability and dividend appeal against patent cliff risks and technical weakness. The stock offers value through consistent cash flow generation and strategic pipeline advancements, but faces headwinds from generic competition and bearish momentum indicators that may pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
